Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats.

Anisimov VN, Khavinson VK, Morozov VG

Biogerontology1 Jan 2000Cited by 18 (Europe PMC)

PMID11707921DOI10.1023/a:1010042008969PepBankPUB-11707921

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In female rats, mean life span was similar with L-Glu-L-Trp and saline.
In plain wordsIn rats, average life span was similar with L-Glu-L-Trp and saline.
Peptide
Thymogen (oglufanide)
Outcome
No significant changeMean life span
Study
ratn = 76
Outbred female rats
Comparator
Normal saline controls
Outcome group
Mortality · Aging and longevity
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Mean life span of rats in both groups was similar
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792101
02AnimalAnimal study (in vivo)Efficacy outcome
In female rats, the Gompertz aging rate was lower with L-Glu-L-Trp than in controls.
In plain wordsIn rats, L-Glu-L-Trp reduced the calculated aging rate compared with controls.
Peptide
Thymogen (oglufanide)
Outcome
DecreaseGompertz aging rate
Study
ratn = 76
Outbred female rats
Comparator
Normal saline controls
Outcome group
Aging markers · Aging and longevity
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Gompertz alpha
0.0071 days-1
controls
Gompertz alpha
0.0041 days-1
L-Glu-L-Trp
Source sentences
Summary
The aging rate indicated as alpha in the Gompertz equation, was 0.0071 days-1 in controls and 0.0041 days-1 in rats exposed to L-Glu-L-Trp.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792104
03AnimalAnimal study (in vivo)Efficacy outcome
In female rats, total tumor incidence was 1.5 times lower with L-Glu-L-Trp than in controls.
In plain wordsIn rats, total tumor incidence was 1.5 times lower with L-Glu-L-Trp than in controls.
Peptide
Thymogen (oglufanide)
Outcome
DecreaseTotal tumor incidence
Study
ratn = 76
Outbred female rats
Comparator
Normal saline controls
Outcome group
Tumor growth · Cancer
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Tumor incidence reduction factor
1.5 times
versus controls
Source sentences
Summary
Total tumor incidence was 1.5 times lower (P < 0.01), malignant tumor incidence 1.7 times lower (P < 0.01), and hematopoietic malignancies (leukemias and lymphomas) 3.4 times lower (P < 0.02) in rats exposed to the dipeptide in comparison with controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792105
04AnimalAnimal study (in vivo)Efficacy outcome
In female rats, malignant tumor incidence was 1.7 times lower with L-Glu-L-Trp than in controls.
In plain wordsIn rats, malignant tumor incidence was 1.7 times lower with L-Glu-L-Trp than in controls.
Peptide
Thymogen (oglufanide)
Outcome
DecreaseMalignant tumor incidence
Study
ratn = 76
Outbred female rats
Comparator
Normal saline controls
Outcome group
Tumor growth · Cancer
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Malignant tumor incidence reduction factor
1.7 times
versus controls
Source sentences
Summary
Total tumor incidence was 1.5 times lower (P < 0.01), malignant tumor incidence 1.7 times lower (P < 0.01), and hematopoietic malignancies (leukemias and lymphomas) 3.4 times lower (P < 0.02) in rats exposed to the dipeptide in comparison with controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792106
05AnimalAnimal study (in vivo)Efficacy outcome
In female rats, hematopoietic malignancy incidence was 3.4 times lower with L-Glu-L-Trp than in controls.
In plain wordsIn rats, blood-system cancer incidence was 3.4 times lower with L-Glu-L-Trp than in controls.
Peptide
Thymogen (oglufanide)
Outcome
DecreaseHematopoietic malignancy incidence
Study
ratn = 76
Outbred female rats
Comparator
Normal saline controls
Outcome group
Tumor growth · Cancer
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Hematopoietic malignancy incidence reduction factor
3.4 times
versus controls
Source sentences
Summary
Total tumor incidence was 1.5 times lower (P < 0.01), malignant tumor incidence 1.7 times lower (P < 0.01), and hematopoietic malignancies (leukemias and lymphomas) 3.4 times lower (P < 0.02) in rats exposed to the dipeptide in comparison with controls.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792107
06AnimalAnimal study (in vivo)Efficacy outcome
Six of 44 L-Glu-L-Trp-treated rats survived beyond the maximum control life span of 965 days.
In plain wordsIn rats, six of 44 treated animals lived longer than the longest-lived control.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseSurvival beyond maximum control life span
Study
ratn = 44
Outbred female rats
Comparator
Normal saline controls
Outcome group
Mortality · Aging and longevity
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Maximum control life span
965 days
controls
Source sentences
Summary
Six out of 44 rats treated with the drug survived over the maximum life span of control rats (965 days).
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792103
07AnimalAnimal study (in vivo)Efficacy outcome
In female rats, life span of the longest-surviving 10% was greater with L-Glu-L-Trp than in controls.
In plain wordsIn rats, the longest-surviving 10% lived longer with L-Glu-L-Trp than controls.
Peptide
Thymogen (oglufanide)
Outcome
IncreaseLife span of longest-surviving 10%
Study
ratn: not reported in source
Outbred female rats
Comparator
Normal saline controls
Outcome group
Mortality · Aging and longevity
Studied dose
5 micrograms/rat, 5 times per week · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
Life span
949 days
longest-surviving 10% of controls
Life span
1048 days
longest-surviving 10% of treated rats
Source sentences
Summary
Mean life span of rats in both groups was similar but that of 10% maximum survived control rats constituted 949 +/- 16.1 days, whereas in the dipeptide-treated rats this value was 1048 +/- 21.1 days (P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of dipeptide on survival, life span and spontaneous tumor development was studied in female rats.
Summary · context
Seventy-six, five-month-old outbred female rats were randomly subdivided into two groups and were subcutaneously injected with 0.2 ml of normal saline (controls, 32 rats) or with 5 micrograms/rat of the dipeptide L-Glu-L-Trp, dissolved in 0.2 ml of saline (44 rats), 5 times per week for 12 months.
Report a problemFND-1170792102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 12:50 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.